The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31

Part of paid clinical trials in San Francisco, California.

Sponsor
Adam Boxer
Study ID
NCT07264283
Phase
PHASE2
Status
Enrolling By Invitation

Conditions

  • PSP - Progressive Supranuclear Palsy

Eligibility Criteria

Sex
ALL
Age
41 Years - 86 Years
Healthy Volunteers
Not accepted

Interventions

  • LM11A-31 — DRUG
    LM11A-31 is administered orally twice daily.
  • Matching Placebo — DRUG
    Matching placebo is administered orally twice daily.

Study Details

The Progressive Supranuclear Palsy Clinical Trial Platform (PTP) is a multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of PSP. Regimen B will evaluate the safety and efficacy of a single study drug, LM11A-31, in participants with PSP.

Key Dates

First listed
Dec 4, 2025
Start date
Jul 29, 2026
Status verified
Nov 2025
Primary completion
Sep 28, 2030
Completion
Sep 28, 2030

Study Design

Enrollment
147 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Regimen B: LM11A-31
  • Placebo Comparator: Matching Placebo

Primary Outcome Measure

Disease progression [ Time Frame: 52 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San Francisco (UCSF), Memory and Aging CenterSan FranciscoCalifornia94158-

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco (UCSF), Memory and Aging Center· San Francisco, CA

Related Studies